Adocia (ADOC) - Total Liabilities
Based on the latest financial reports, Adocia (ADOC) has total liabilities worth €26.96 Million EUR (≈ $31.52 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Adocia long-term investment allocation to see how much of total assets are deployed in long-term investments.
Adocia - Total Liabilities Trend (2008–2025)
This chart illustrates how Adocia's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Adocia.
Adocia Competitors by Total Liabilities
The table below lists competitors of Adocia ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Air T Inc
NASDAQ:AIRT
|
USA | $385.90 Million |
|
Frontier Energy Ltd
AU:FHE
|
Australia | AU$5.64 Million |
|
MLRN Projects and Trade Ltd
TA:MLRN
|
Israel | ILA807.85 Million |
|
Samsung Pharm
KO:001360
|
Korea | ₩44.04 Billion |
|
Semyung Electric Machinery Co.Ltd
KQ:017510
|
Korea | ₩20.49 Billion |
|
Dong Yang Pipe
KO:008970
|
Korea | ₩98.08 Billion |
|
MEGA International Development Co Ltd
TWO:5529
|
Taiwan | NT$3.29 Billion |
|
Tah Kong Chemical Industrial
TWO:4706
|
Taiwan | NT$132.58 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Adocia's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Adocia to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 18.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adocia's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adocia (2008–2025)
The table below shows the annual total liabilities of Adocia from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €26.96 Million ≈ $31.52 Million |
-10.45% |
| 2024-12-31 | €30.11 Million ≈ $35.20 Million |
-5.53% |
| 2023-12-31 | €31.87 Million ≈ $37.26 Million |
-26.88% |
| 2022-12-31 | €43.58 Million ≈ $50.95 Million |
-0.65% |
| 2021-12-31 | €43.87 Million ≈ $51.29 Million |
+12.97% |
| 2020-12-31 | €38.83 Million ≈ $45.40 Million |
+14.50% |
| 2019-12-31 | €33.91 Million ≈ $39.65 Million |
+40.17% |
| 2018-12-31 | €24.20 Million ≈ $28.29 Million |
+43.13% |
| 2017-12-31 | €16.90 Million ≈ $19.76 Million |
-53.09% |
| 2016-12-31 | €36.04 Million ≈ $42.13 Million |
-12.20% |
| 2015-12-31 | €41.04 Million ≈ $47.98 Million |
-17.98% |
| 2014-12-31 | €50.04 Million ≈ $58.50 Million |
+793.71% |
| 2013-12-31 | €5.60 Million ≈ $6.55 Million |
-58.83% |
| 2012-12-31 | €13.60 Million ≈ $15.90 Million |
+2.20% |
| 2011-12-31 | €13.31 Million ≈ $15.56 Million |
+204.07% |
| 2010-12-31 | €4.38 Million ≈ $5.12 Million |
+0.74% |
| 2009-12-31 | €4.34 Million ≈ $5.08 Million |
+17.79% |
| 2008-12-31 | €3.69 Million ≈ $4.31 Million |
-- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more